10 Under-the-Radar Stocks with Massive Upside for 2025

2. Sensus Healthcare, Inc. (NASDAQ:SRTS)

Upside Potential: 72.67%

Stock Price as of January 18: $6.66

Number of Hedge Fund Investors: 8

Sensus Healthcare, Inc. (NASDAQ:SRTS) is a leading medical technology company specializing in the development and distribution of innovative, non-invasive solutions for the treatment of non-melanoma skin cancer and keloid scars. The company’s flagship product, the SRT-100 Vision, is an image-guided SRT system that offers a cost-effective and clinically proven alternative to more invasive procedures such as the Mohs surgery.

Sensus Healthcare, Inc. (NASDAQ:SRTS) is actively expanding into new markets to diversify its revenue streams and increase its market presence. The company has made significant inroads into the radiation oncology market, with a recent sale to Swedish Hospital in Seattle, part of the prestigious Providence Health and Services network. This sale represents a valuable entry point into hospital oncology departments, where SRT is seen as a cost-effective and clinically proven alternative to more expensive linear accelerators and electron beam radiation systems.

Sensus Healthcare, Inc. (NASDAQ:SRTS) is also exploring international markets, particularly in Asia and the Middle East. The company shipped a system to a hospital in Israel and has made a sale to a veterinary specialist referral center in Tel Aviv. The veterinary market is an incremental growth opportunity, with institutions such as Colorado State University’s College of Veterinary Medicine using Sensus Healthcare, Inc.’s (NASDAQ:SRTS) SRT systems to treat a variety of animal tumors. Furthermore, Sensus Healthcare, Inc. (NASDAQ:SRTS) is actively developing new products and technologies to expand its offerings and maintain its competitive edge. One such initiative is the Transdermal Infusion Product (TBI), which is being developed with feedback from key opinion leaders and pharmaceutical companies.